| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 9,306,438 | 10,305,320 | ||
| Accounts receivable | 4,155,599 | 3,587,560 | ||
| Inventory | 14,063,706 | 13,018,702 | ||
| Prepaid expenses | 441,489 | 939,436 | ||
| Total current assets | 27,967,232 | 27,851,018 | ||
| Total | 1,060,556 | - | ||
| Less accumulated depreciation | 462,469 | - | ||
| Property & equipment | 598,087 | 638,354 | ||
| Intangible assets | 2,009,337 | 2,490,827 | ||
| Deferred tax asset | 92,234 | 92,234 | ||
| Right-of-use-asset | 820,489 | 892,817 | ||
| Total long-term assets | 3,520,147 | 4,114,232 | ||
| Total assets | 31,487,379 | 31,965,250 | ||
| Accounts payable & accrued expenses | 6,137,465 | 4,797,465 | ||
| Earnout payable | 295,797 | 295,797 | ||
| Income tax payable | 0 | 258,158 | ||
| Right-of-use-liability | 218,053 | 222,496 | ||
| Total current liabilities | 6,651,315 | 5,573,916 | ||
| Right-of-use-liability | 636,708 | 706,530 | ||
| Total long-term liabilities | 636,708 | 706,530 | ||
| Total liabilities | 7,288,023 | 6,280,446 | ||
| Preferred stock series b 0.10 par value per share 1,000,000 shares authorized 130,000 shares issued and outstanding | 13,000 | 13,000 | ||
| Common stock 0.001 par value per share 3,000,000,000 shares authorized 4,555,945 and 2,580,098 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 4,555 | 4,555 | ||
| Capital paid in excess of par value | 97,376,841 | 97,376,841 | ||
| Accumulated comprehensive income | -320,841 | 280,787 | ||
| Accumulated (deficit) | -72,874,199 | -71,990,379 | ||
| Total shareholders' equity | 24,199,356 | 25,684,804 | ||
| Total liabilities and shareholders' equity | 31,487,379 | 31,965,250 | ||
Sunshine Biopharma Inc. (SBFMW)
Sunshine Biopharma Inc. (SBFMW)